Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Up 8.9% in June

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 1,100,000 shares, a growth of 8.9% from the June 15th total of 1,010,000 shares. Based on an average daily volume of 157,000 shares, the days-to-cover ratio is currently 7.0 days. Currently, 3.1% of the shares of the stock are sold short.

Athira Pharma Stock Performance

NASDAQ:ATHA opened at $3.40 on Thursday. The company has a market cap of $130.32 million, a price-to-earnings ratio of -1.11 and a beta of 2.90. The stock’s fifty day moving average price is $2.62 and its two-hundred day moving average price is $2.78. Athira Pharma has a 52-week low of $1.33 and a 52-week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last released its earnings results on Wednesday, May 15th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.11. On average, equities analysts predict that Athira Pharma will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $19.00 target price on shares of Athira Pharma in a research note on Thursday, June 20th.

Insider Buying and Selling

In other news, Director Kelly A. Romano acquired 15,000 shares of the company’s stock in a transaction dated Friday, June 21st. The stock was bought at an average price of $2.26 per share, with a total value of $33,900.00. Following the completion of the acquisition, the director now owns 53,315 shares in the company, valued at approximately $120,491.90. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Athira Pharma news, Director Kelly A. Romano purchased 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was purchased at an average cost of $2.26 per share, with a total value of $33,900.00. Following the acquisition, the director now directly owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kelly A. Romano acquired 27,400 shares of Athira Pharma stock in a transaction on Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, for a total transaction of $66,308.00. Following the purchase, the director now owns 80,715 shares of the company’s stock, valued at approximately $195,330.30. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ATHA. Perceptive Advisors LLC grew its position in shares of Athira Pharma by 12.6% during the 4th quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock worth $13,129,000 after buying an additional 605,686 shares during the period. Private Advisor Group LLC acquired a new stake in Athira Pharma during the 4th quarter worth $32,000. Clarius Group LLC raised its position in shares of Athira Pharma by 35.8% during the 4th quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock valued at $130,000 after acquiring an additional 14,124 shares during the last quarter. Forefront Analytics LLC lifted its stake in shares of Athira Pharma by 43.0% in the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after purchasing an additional 8,955 shares during the period. Finally, Mirador Capital Partners LP acquired a new position in shares of Athira Pharma in the 1st quarter valued at $57,000. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.